





The **Library of RNA-Binding Protein Ligands** is a comprehensive collection of 316 ligands designed to target key RNA-binding proteins (RBPs) involved in crucial cellular processes. This library contains pre-synthesized ligands, ready to support a wide range of experimental applications in RNA biology and drug discovery. Each ligand in the collection is meticulously characterized, providing in-depth data on target interactions and biochemical properties, ensuring researchers have the critical information needed to drive meaningful discoveries in RNA-related pathways. This ready-to-use resource is ideal for advancing studies in translation regulation, RNA metabolism, gene expression control, and immune responses.

The library aims to accelerate innovation in fundamental research and therapeutic development, empowering researchers to explore the dynamic roles of RNA-binding proteins in disease and biology.


Related terms: RNA-binding, Lysine-tRNA ligase, Nucleophosmin, Polyadenylate-binding protein.




Highlights




EBC-08851
2-(3-Oxobenzo[d]isothiazol-2(3H)-yl)-N-(1-adamantyl)acetamide shows inhibitory activity against sortase A.



EBC-00690
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase.



EBC-218031
SU9516 is a potent and selective CDK2 inhibitor, with an IC50 of 17.3 nM.



EBC-386047
PD 173955 is a tyrosine kinase inhibitor. It inhibits Bcr-Abl and c-Kit (IC50s = 1-2 and 25 nM, respectively).

Library Composition

Name	Occurrence in the library, times
Polyadenylate-binding protein 1	261
Bromodomain adjacent to zinc finger domain protein 2A	25
Histone-lysine N-methyltransferase EZH2	6
Interferon-induced, double-stranded RNA-activated protein kinase	5
Bifunctional glutamate/proline--tRNA ligase	5
Nucleophosmin	5
TAR DNA-binding protein 43	4
Lysine--tRNA ligase	2
ELAV-like protein 1	1
Breast cancer type 1 susceptibility protein	1
Werner syndrome ATP-dependent helicase	1